Trials
4 active
14 in total · 4 in the EU
Targets
—
None known yet
What this is
- How it works
- Cholinesterase Inhibitor FDA class
- Tested for
- Alzheimers Disease
- Main trialPhase 1
- “The primary purpose of this study is to evaluate proof of mechanism (POM) and long-term safety and tolerability of E2511 in participants with Early AD. The study consists of 2 parts. In Part A, participants will be randomly assigned to receive either E2511 or donepezil. In Part B, participants will receive E2511 only. Once Part A and Part B participants complete the Core Trial (which includes Pretreatment and Treatment phases) they will have the option to enter the Extension Phase where they will receive E2511 for 18 months.”In the company’s words, NCT07768592 on ClinicalTrials.gov
- Other names
- E2022 Tape · Aricept · E2020
Other drugs for Alzheimers Disease
- Xanomeline/Trospium ChlorideBristol Myers Squibb · Phase 3
- -APN-1607JYAMS PET Research & Development Limited · Phase 3
- LecanemabEisai · Biogen · Phase 3
- DMB-IBigespas LTD · Phase 3
- TrontinemabRoche · Phase 3
- Buntanetap/posiphenAnnovis Bio Inc. · Phase 3
Copies tested against it3
Other companies’ versions, mostly cheaper copies for when the patent ends
- Donepezil TDSCorium, Inc. · NCT04617782 · finished
- GB-5001AG2GBio, Inc. · NCT07799090 · finished
- Donepezil patchIcure Pharmaceutical Inc. · NCT03197740 · finished
Coming up1
- 6 May 2030Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials14
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 6 May 2030 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease (AD) | |
| Phase 4Completed | 31 Jul 2006 | Alzheimer's Disease Long-term Follow-up Study (ALF Study) | |
| Phase 4Completed | 15 Aug 2008 | Neural Correlates In Mild Alzheimer's Disease | |
| Phase 4Completed | 31 Aug 2008 | The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease | |
| Phase 3Completed | 26 May 2009 | Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment | |
| Phase 3Completed | 1 Apr 2010 | Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease | |
| Phase 3Completed | Mar 2013 | A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase | |
| Phase 2Completed | 5 Sep 2008 | Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome | |
| Phase 2Terminated | 13 Nov 2008 | Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial | |
| Phase 1Completed | Apr 2013 | A Phase 1 Study of E2022 Tape Formulation for Different Application Sites and Intervals in Japanese Healthy Elderly Males | |
| Phase 2Authorised | not given | Multicenter, randomized, double-blind, and placebo-controlled clinical trial to assess the efficacy and safety of donepezil versus placebo in mild cognitive impairment associated with Parkinson's disease. | |
| Phase 2Authorised | not given | Treatment with acetylcholine esterase inhibitors in anorexia nervosa : a multicenter double-blind randomised controlled trial versus placebo | |
| Phase 2Ended | not given | Impact of CHOlinergic Stimulation on COgnitive and MOtor Functions and Brain Activity in Elderly Volunteers (CHOCOMO) - a randomised, placebo-controlled trial | |
| Phase 4Authorised | not given | CHOLINE-2 - Donepezil Versus Non-drug Treatment in Alzheimer's Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026